Rights and permissions
About this article
Cite this article
Nilotinib favourable costs over dasatinib in CML . . .. Pharmacoecon. Outcomes News 605, 13 (2010). https://doi.org/10.2165/00151234-201006050-00022
Published:
Issue Date:
DOI: https://doi.org/10.2165/00151234-201006050-00022